SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors
| Autor: | Merry Chen, Patrick Y. Wen, David Schiff, Padmaja Kandula, Tobias Walbert, Elizabeth R. Gerstner, Wolfgang Wick, Edward K. Avila, Jong Woo Lee, Emilie Le Rhun, Rebecca Harrison, Michael Weller, Michael A. Vogelbaum, Glen Stevens |
|---|---|
| Přispěvatelé: | University of Zurich, INSERM, Université de Lille, Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 (PRISM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille) |
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
Pediatrics medicine.medical_specialty Neurology seizure [SDV]Life Sciences [q-bio] medicine.medical_treatment Brain tumor 610 Medicine & health Guidelines GBM 10180 Clinic for Neurosurgery antiepileptic drug glioma Glioma medicine Valproic Acid guideline business.industry Guideline medicine.disease 10040 Clinic for Neurology Anticonvulsant Systematic review Oncology Neurology (clinical) Levetiracetam business medicine.drug |
| Zdroj: | Neuro Oncol Neuro-Oncology Neuro-Oncology, 2021, Neuro-Oncology, 23 (11), pp.1835-1844. ⟨10.1093/neuonc/noab152⟩ |
| ISSN: | 1523-5866 1522-8517 |
| DOI: | 10.1093/neuonc/noab152 |
| Popis: | Objective To update the 2000 American Academy of Neurology (AAN) practice parameter on anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Methods Following the 2017 AAN methodologies, a systematic literature review utilizing PubMed, EMBASE Library, Cochrane, and Web of Science databases was performed. The studies were rated based on the AAN therapeutic or causation classification of evidence (class I-IV). Results Thirty-seven articles were selected for final analysis. There were limited high-level, class I studies and mostly class II and III studies. The AAN affirmed the value of these guidelines. Recommendations In patients with newly diagnosed brain tumors who have not had a seizure, clinicians should not prescribe antiepileptic drugs (AEDs) to reduce the risk of seizures (level A). In brain tumor patients undergoing surgery, there is insufficient evidence to recommend prescribing AEDs to reduce the risk of seizures in the peri- or postoperative period (level C). There is insufficient evidence to support prescribing valproic acid or levetiracetam with the intent to prolong progression-free or overall survival (level C). Physicians may consider the use of levetiracetam over older AEDs to reduce side effects (level C). There is insufficient evidence to support using tumor location, histology, grade, molecular/imaging features when deciding whether or not to prescribe prophylactic AEDs (level U). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|